65% believe this impact will be substantial SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2024 / AKASA , the preeminent provider of end-to-end generative AI (GenAI) solutions for the revenue cycle, today announced findings from a survey highlighting that 90% of revenue cycle leaders believe GenAI will have an impact on their medical coding operations, with 65% saying that impact will be substantial. Survey responses reveal that 45% of healthcare leaders are optimistic that GenAI will...